PFO Closure + Prasugrel for Migraine

(COMFORT-PFO Trial)

This trial explores whether closing a small heart opening, known as a patent foramen ovale (PFO), can reduce migraines in patients who have already experienced improvements with the blood thinner prasugrel. The study aims to determine if closing the PFO provides longer-lasting migraine relief after stopping the medication, compared to continuing prasugrel for a period before discontinuation. Participants whose migraines improve on prasugrel will either continue the medication or have the PFO closed and then continue prasugrel for a short time. This trial may suit individuals who have suffered from migraines for over a year, occurring more than once a week, and who find relief with prasugrel. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking advancements in migraine treatment.

The trial requires that if you are taking preventive migraine medications, you must keep the dose stable for at least 3 months before the trial and continue at the same dosage during the study. If you need daily NSAIDs for reasons other than migraines, you cannot participate.

Earlier research has shown that closing a patent foramen ovale (PFO) using a catheter is safe. Many patients experienced a significant reduction in migraine days after the procedure, with some reporting up to an 80% decrease in monthly migraines. This minimally invasive procedure involves small incisions and typically allows for a quick recovery.

Researchers are excited about these treatments because they offer a novel approach to managing migraines. Unlike typical migraine treatments that often involve pain relief medications like triptans or preventive medications such as beta-blockers, this trial investigates the combination of prasugrel, a thienopyridine medication, and the physical closure of a patent foramen ovale (PFO), a small hole in the heart. Prasugrel is unique in its ability to reduce headache frequency, potentially offering a new preventive mechanism. Additionally, the PFO closure procedure is a non-surgical catheter-based intervention that might address a structural cause of migraines. This dual approach could open up new possibilities for patients who haven't found relief with standard migraine treatments.

Research has shown that prasugrel, a medication that prevents blood cells from sticking together, can help reduce migraines, with about 64% of users experiencing fewer migraines. In this trial, participants in Group A will receive prasugrel alone. For those with a small heart opening called a PFO, closing this opening has shown promise, with studies finding that up to 88.7% of patients report fewer migraines after the closure. Participants in Group B of this trial will undergo PFO closure in addition to receiving prasugrel. Both treatments may offer relief, especially for those who initially respond well to prasugrel.⁶⁷⁸⁹¹⁰